Stanniocalcin-1 (STC-1) therapy for treatment of retinal diseases
US9498517B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 1, 2015 |
| Grant date | Nov 22, 2016 |
| Priority date | — |
| Expiry date | Jul 1, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/575
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.